LDL receptor-mediated endocytosis of Escherichia coli α-hemolysin mediates renal epithelial toxicity
- PMID: 40504153
- PMCID: PMC12184420
- DOI: 10.1073/pnas.2505482122
LDL receptor-mediated endocytosis of Escherichia coli α-hemolysin mediates renal epithelial toxicity
Abstract
The α-hemolysin (HlyA) of uropathogenic Escherichia coli (UPEC) is a pore-forming toxin (PFT) that is thought to function by disrupting the host cell plasma membrane. Although CD18 (LFA-1) has been implicated as a receptor on myeloid cells, the mechanisms underlying HlyA cytotoxicity to epithelial cells are poorly defined. Here, we show that HlyA secretion by UPEC markedly intensifies renal tubular epithelial injury in a murine model of ascending pyelonephritis. A CRISPR-Cas9 loss-of-function screen in renal collecting duct cells revealed an unexpected requirement for clathrin-mediated endocytosis in HlyA-induced cytotoxicity. Following internalization, HlyA triggered lysosomal permeabilization, resulting in protease leakage, cytoplasmic acidification, and mitochondrial impairment, culminating in rapid epithelial cell death-a pathway distinct from canonical membrane-disrupting mechanisms of other PFTs. Moreover, we identify the low-density lipoprotein receptor (LDLR) as a critical epithelial receptor for HlyA; genetic ablation or competitive inhibition of the HlyA-LDLR interaction fully abrogated cytotoxicity. Our findings detail a paradigm for HlyA function in which epithelial toxicity relies on LDLR-mediated endocytic uptake rather than plasma membrane poration. These mechanistic insights illuminate potential therapeutic strategies to attenuate HlyA-mediated tissue damage during UPEC infections.
Keywords: LDLR; RTX toxin; hemolysin.
Conflict of interest statement
Competing interests statement:M.S.D. is a consultant or advisor for Inbios, Moderna, IntegerBio, Merck, GlaxoSmithKline, Bavarian Nordic, and Akagera Medicines. D.A.H. serves on the Board of Directors of BioVersys AG. D.A.H. holds stock options exceeding $5,000 in BioVersys AG.
References
-
- Chacko F. M., Schmitt L., Interaction of RTX toxins with the host cell plasma membrane. Biol. Chem. 404, 663–671 (2023). - PubMed
-
- Shaikh N., et al. , Early antibiotic treatment for pediatric febrile urinary tract infection and renal scarring. JAMA Pediatr. 170, 848–854 (2016). - PubMed
-
- Shaikh N., Ewing A. L., Bhatnagar S., Hoberman A., Risk of renal scarring in children with a first urinary tract infection: A systematic review. Pediatrics 126, 1084–1091 (2010). - PubMed
MeSH terms
Substances
Grants and funding
- R01 AI158418/AI/NIAID NIH HHS/United States
- T32-GM007067/HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- R01-DK126697/HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- F31-AI176711/HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- T32 GM007067/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources